Abstract
Background Higher maternal pre-pregnancy body mass index (BMI) has been associated with higher risk of stillbirth, infant and neonatal mortality. Few studies have explored associations of underweight, with those that have varying in their conclusions. Our aim was to examine the risk of stillbirth, infant and neonatal mortality across the pre-pregnancy BMI distribution and establish a likely healthy BMI range.
Methods We used publicly available birth, infant death and fetal death datasets from the US National Center for Health Statistics National Vital Statistics System, 2014–2020. Fractional polynomial multivariable logistic regression was used to examine the nature of associations between maternal pre-pregnant BMI and stillbirth (birth with no signs of life at ≥24 weeks), infant mortality (death of a live born baby aged <365 days) and neonatal mortality (death of a live born baby aged <28 days).
Findings There were 56,376/21,437,556 (0.26%) stillbirths, 108,413/24,742,273 (0.44%) infant deaths and 66,801/24,742,273 (0.27%) neonatal deaths among complete cases. Mean BMI was 27.0 kg/m2. We found non-linear associations between pre-pregnant BMI and all three outcomes - risk was elevated at both low and high BMIs although, for stillbirth, the increased risk at low BMI was less marked than for infant and neonatal mortality. The lowest risk was at a BMI of 21 kg/m2 for infant and neonatal mortality and, for stillbirth, at 18 kg/m2.
Interpretation Public health messaging for preconception and postnatal care should focus on healthy weight to maximise maternal and child health, and not focus solely on maternal overweight or obesity.
Competing Interest Statement
DAL has received support from Medtronic Ltd and Roche Diagnostics for research unrelated to that presented here. HVT and RC declare they have no competing interests.
Funding Statement
The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement (Grant number 669545; DevelopObese), the US National Institute of Health (R01 DK10324) and the Bristol NIHR biomedical research centre. RC and DAL work in a unit that receives support from the University of Bristol and UK Medical research Council (MC_UU_00011/6). DAL is a National Institute of Health Research Senior Investigator (NF-0616-10102).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available data available from the National Center for Health Statistics: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in this study are available online at